Product
AI AGENTS
AI APPLICATIONS
OTHERS
Solutions
INDUSTRIES
USE CASES
Pricing
Resources
EXPLORE
ENGAGE
SUPPORT & SERVICES
About
PatSnap Eureka Platform
Agents for IP
Agents for Engineering
Agents for Life Sciences
Agents for Materials
PatSnap Eureka Desktop
NEWAnalytics
IP IntelligenceSynapse
Biopharma IntelligenceBio
Biosequence Search and AnalysisChemical
Chemical Structure Search and AnalysisOpen Platform
NEWProfessional Services
Customer Stories
Newsroom
Blog
Global Innovation Report
Glossary
Webinars & Training
Frontier
User Community
R&D Benchmark Calculator
Trust and Security
PatentBench
NEWLLM
Help center
Careers
Access to over 2,000,000,000 structured data points around patents, science, litigation, and tech sectors
Innovate 75% faster at 25% less cost
Cloud or on-prem for maximum privacy and control
Trusted by more than 18,000 innovators worldwide
To use , click the vertification button in the email we sent to [email protected].
This helps keep your account secure.
You should receive it shortly. Don’t forget to check your spam folder.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Thoughtfully curated series offering valuable insights for innovation professionals
Article | Report Novo Nordisk's Mim8 bispecific antibody targets FIXa and FX to challenge Hemlibra in hemophilia A. Explore the clinical, IP, and competitive landscape ahead of the FDA decision.
Article | Report No patent or literature data was available to support this article. Learn how to expand your search for deep space radiation qualification research using PatSnap Eureka.
Article | Report How cerebral organoid maturation is evolving in 2026: vascularization breakthroughs, bioreactor engineering, epigenetic benchmarking, and the IP landscape mapped.
Article | Report Faricimab (Vabysmo) expands into RVO and DME with treat-and-extend dosing up to 16 weeks. Analyse Roche's dual VEGF/Ang-2 IP strategy and competitive durability data.
Article | Report How AI transforms competitive benchmarking workflows for R&D teams evaluating new technology platforms — from patent landscape analysis to decision support.
Article | Report How neural operators, GPU acceleration, and physics-informed AI are cutting turbulence simulation times by up to 1000×. The 2026 technology landscape from PatSnap.
Article | Report How Ocular Therapeutix's axitinib intravitreal implant (OTX-TKI) competes in the bioerodible depot vs. port delivery race for wet AMD. Patent landscape analysis.
Article | Report How do engineers choose between sintering and hot pressing for advanced technical ceramics? Explore key selection criteria, microstructural outcomes, and industrial applications.
Article | Report Prime editing's 2026 technology landscape: pegRNA engineering, off-target safety, 56,000 ClinVar variants, delivery bottlenecks, and the race to first-in-human trials.
Article | Report Spatial genomics maps gene expression to tissue locations, reshaping oncology, neuroscience and biodiversity. Explore the 2026 technology landscape and key innovation signals.
Article | Report Zilebesiran (ALN-AGT) targets hepatic AGT via GalNAc-siRNA to suppress RAAS upstream. Explore Phase 3 KARDIA data, IP landscape, and competitive threats in resistant hypertension.
Article | Report How AI-powered defect classification improves first-pass yield in PCB assembly inspection—covering AOI, deep learning, solder joint detection, and false-call reduction.
Article | Report A 2026 patent and literature landscape of autonomous vehicle HD map technology — covering map generation, V2X updates, interoperability, and AI-driven utilization.
Article | Report How engineers validate sealing integrity of implantable medical device enclosures under ISO 11607 sterile barrier requirements — methods, standards, and tools.
Article | Report CT-388 and petrelintide are competing in next-generation obesity pharmacotherapy. Explore the GLP-1/GIP dual agonist and amylin receptor agonist landscape, IP signals, and clinical race.